The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of UGT1A1 genotype on prognosis in Japanese advanced colorectal cancer patients treated by irinotecan-based regimens.
 
Wataru Ichikawa
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Daiichi Sankyo; Merck Serono; Zeria Pharmaceutical
Research Funding - Taiho Pharmaceutical; Takeda
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Keisuke Uehara
No Relationships to Disclose
 
Keisuke Minamimura
Research Funding - Daiichi Sankyo (Inst)
 
Chihiro Tanaka
No Relationships to Disclose
 
Yasumasa Takii
Research Funding - Daiichi Sankyo (Inst)
 
Hideaki Miyauchi
Research Funding - Daiichi Sankyo (Inst)
 
Sotaro Sadahiro
Honoraria - Daiichi Sankyo
Research Funding - Daiichi Sankyo (Inst)
 
Katsunori Shinozaki
Honoraria - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Merck Serono; Mochida Pharmaceutical Co. Ltd.; Ono Pharmaceutical; Otsuka; Shionogi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Kanehisa Fukumoto
No Relationships to Disclose
 
Toshio Otsuji
Research Funding - Daiichi Sankyo (Inst)
 
Takeshi Kambara
Research Funding - Daiichi Sankyo (Inst)
 
Satoshi Morita
Honoraria - Chugai Pharma; Daiichi Sankyo; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Taiho Pharmaceutical
Research Funding - Daiichi Sankyo (Inst)
 
Yuichi Ando
Honoraria - ARKRAY; ASKA Pharmaceutical Co; AstraZeneca; Bayer; Benesse Style Care; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Hisamitsu Pharmaceutical; Janssen; Kowa; Kyowa Hakko Kirin; Lilly Japan; Meiji Seika Kaisha; Merck Serono; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; GlaxoSmithKline; Kowa; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Parexel
Research Funding - Chugai Pharma (Inst); Hisamitsu Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); Mitsubishi Tanabe Pharma (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Kayaku (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Torii Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Yukihiro Okutani
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Masahiro Sugihara
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Eisai
Patents, Royalties, Other Intellectual Property - Daiichi Sankyo
 
Toru Sugiyama
Honoraria - Daiichi Sankyo
Consulting or Advisory Role - Daiichi Sankyo
 
Yasuo Ohashi
Leadership - Statcom
Stock and Other Ownership Interests - Statcom
Honoraria - Chugai Pharma; DNP Media Create; Sanofi; Shionogi
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - Astellas Pharma (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Yakult Honsha
 
Yuh Sakata
Honoraria - Daiichi Sankyo; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo